155 related articles for article (PubMed ID: 36478592)
21. Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma.
Lorenzo-Sanz L; Lopez-Cerda M; da Silva-Diz V; Artés MH; Llop S; Penin RM; Bermejo JO; Gonzalez-Suarez E; Esteller M; Viñals F; Espinosa E; Oliva M; Piulats JM; Martin-Liberal J; Muñoz P
Nat Commun; 2024 Jun; 15(1):5352. PubMed ID: 38914547
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
Saglam O; Zhou J; Wang X; Conejo-Garcia JR
Int J Gynecol Pathol; 2020 Sep; 39(5):428-435. PubMed ID: 31274701
[TBL] [Abstract][Full Text] [Related]
23. NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.
Zheng S; Liu Q; Liu T; Yang L; Zhang Q; Shen T; Zhang X; Han X; Lu X
Biochem Biophys Res Commun; 2020 May; 526(1):29-34. PubMed ID: 32192776
[TBL] [Abstract][Full Text] [Related]
24. Expression of PSCA, PIWIL1 and TBX2 and its correlation with HPV16 infection in formalin-fixed, paraffin-embedded cervical squamous cell carcinoma specimens.
Liu WK; Jiang XY; Zhang ZX
Arch Virol; 2010 May; 155(5):657-63. PubMed ID: 20229117
[TBL] [Abstract][Full Text] [Related]
25. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
27. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
[TBL] [Abstract][Full Text] [Related]
28. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
29. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNA SCARNA2 induces cutaneous squamous cell carcinoma progression via modulating miR-342-3p expression.
Zhang Z; Jia M; Wen C; He A; Ma Z
J Gene Med; 2020 Dec; 22(12):e3242. PubMed ID: 32558970
[TBL] [Abstract][Full Text] [Related]
31. CD271 activation prevents low to high-risk progression of cutaneous squamous cell carcinoma and improves therapy outcomes.
Quadri M; Tiso N; Musmeci F; Morasso MI; Brooks SR; Bonetti LR; Panini R; Lotti R; Marconi A; Pincelli C; Palazzo E
J Exp Clin Cancer Res; 2023 Jul; 42(1):167. PubMed ID: 37443031
[TBL] [Abstract][Full Text] [Related]
32. [Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
Yang LS; Shi CY; Liang YH; Liu T; Hou XR; Tian XD; Wang XY
Hua Xi Kou Qiang Yi Xue Za Zhi; 2019 Oct; 37(5):516-520. PubMed ID: 31721500
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
34. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
[TBL] [Abstract][Full Text] [Related]
36. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
[TBL] [Abstract][Full Text] [Related]
37. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Yoshino H; Sato Y; Nakano M
Curr Issues Mol Biol; 2021 May; 43(1):153-162. PubMed ID: 34069326
[TBL] [Abstract][Full Text] [Related]
38. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
39. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.
Zhang W; Pang Q; Zhang X; Yan C; Wang Q; Yang J; Yu S; Liu X; Pan Y; Yuan Z; Wang P; Xiao Z
Cancer Sci; 2017 Apr; 108(4):590-597. PubMed ID: 28192623
[TBL] [Abstract][Full Text] [Related]
40. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
Deepak HB; Prince SE; Deshpande P
Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]